PDS Biotechnology Corporation (PDSB) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Per the Roarable RQD rating, PDSB scores 45 out of 100, earning a D grade and the verdict "Roarable Sell — Underperform / Distribution Warning." Pillar scores are: Fundamental Cash Engine 8/20 (ROIC -35%; FCF yield -17.05%), Whale 13F Flow 12/20 (institutional accumulation and options positioning), Insider Conviction 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 12/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 10/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5). The weakest pillar is Insider Conviction, and the strongest relative pillars are Whale 13F Flow and Macro Regime Fit, each at 12/20. The cash engine pillar is the most concerning in absolute terms, given negative ROIC and negative FCF yield. For a prospective investor, the rating indicates that the current profile is weighted toward underperformance and distribution risk rather than cash generation. Any upside case would need to rest on factors outside reported operating economics, such as institutional accumulation or sector-level re-rating, which the rating itself does not treat as sufficient to offset the weaker fundamentals and insider picture. This is an analytical summary, not personalized financial advice.

Reported revenue is $0.0M across all three listed periods, and operating and net losses are reported in each. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Reported cash declined from $41.7M in FY 2024 to $26.7M in FY 2025, while debt is listed as N/A in the source data.

Per the recent news and catalysts feed, six items relate to PDSB. Items flagged as CATALYST include a Yahoo Finance report on an upgrade to Buy, a Timothy Sykes report headlined that PDSB jumped on Phase 2 data and a Nant deal, and a StocksToTrade report on a volatile surge attracting momentum traders. Items flagged as MARKET WIRE include a Seeking Alpha slideshow on PDS-0301 immunocytokine in metastatic colorectal cancer, a Stock Titan report on a National Cancer Institute investigator's presentation of an experimental colorectal cancer treatment, and a Simply Wall St forecast and analyst predictions page. The headlines reference a Phase 2 data readout and a Nant deal; the underlying details of those items are not available in source data. Risk watch items include the volatility described in the momentum-trader report and the fact that the upgrade claim is not corroborated by analyst data in this dossier. Per the Butterfly Supply-Chain Graph, no proprietary signals or butterfly links are listed.

Per the Butterfly Supply-Chain Graph, supply chain status is NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies are not available in source data. Sector correlations beyond the stated Health Care / Biotechnology classification are not available in source data. Second-order bottlenecks are not available in source data. Investors should note that the absence of mapped links means this dossier cannot identify ripple effects from partners, suppliers, or customers.

• What are the specific Phase 2 results and Nant deal terms referenced in the news headlines, and how do they affect the reported cash balance and debt position?
• What is the company's cash runway given reported cash of $26.7M against FY 2025 negative FCF of $-27.8M?
• Why is debt reported as N/A, and what is the complete capital structure behind the Debt/Equity figure of 0.5?
• What are the institutional 13F holdings and insider Form 4 transactions that underpin the whale and insider pillar scores?
• What are the EPS and P/E figures that would allow valuation comparison, given that these are not available in source data?